High levels of phosphatase and tensin homolog expression are associated with tumor progression, tumor recurrence, and systemic metastases in pt1 urothelial carcinoma of the bladder: A tissue microarray study of 156 patients treated by transurethral resection

Urology

Volumn 81, Issue 1, 2013, Pages 116-122

  Chaux, Alcides ^a   Compérat, Eva ^a   Varinot, Justine ^a   Hicks, Jessica ^a   Lecksell, Kristen ^a   Solus, Jason ^a   Netto, George J ^a,b  

^a not available

^b DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; MITOMYCIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN S6;

BLADDER CARCINOMA; BLADDER SURGERY; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURGERY; CONFERENCE PAPER; CONTROLLED STUDY; ENZYME BLOOD LEVEL; ENZYME PHOSPHORYLATION; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TISSUE MICROARRAY; TRANSITIONAL CELL CARCINOMA; TUMOR GROWTH; TUMOR RECURRENCE;

EID: 84871984110     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2012.09.007     Document Type: Conference Paper

References (24)

1. C.B. Ching, and D.E. Hansel Expanding therapeutic targets in bladder cancer: the PI3K/Akt/mTOR pathway Lab Invest 90 2010 1406 1414
2. L. Schultz, A. Chaux, and R. Albadine Immunoexpression status and prognostic value of mTOR and hypoxia-induced pathway members in primary and metastatic clear cell renal cell carcinomas Am J Surg Pathol 35 2011 1549 1556
3. T.L. Lotan, B. Gurel, and S. Sutcliffe PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients Clin Cancer Res 17 2011 6563 6573
4. J.A. Garcia, and D. Danielpour Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies Mol Cancer Ther 7 2008 1347 1354
5. J.J. Mansure, R. Nassim, and S. Chevalier Inhibition of mammalian target of rapamycin as a therapeutic strategy in the management of bladder cancer Cancer Biol Ther 8 2009 2339 2347
6. I. Makhlin, J. Zhang, and C.J. Long The mTOR pathway affects proliferation and chemosensitivity of urothelial carcinoma cells and is upregulated in a subset of human bladder cancers BJU Int 108 2011 E84 E90
7. C.N. Qian, K.A. Furge, and J. Knol Activation of the PI3K/AKT pathway induces urothelial carcinoma of the renal pelvis: identification in human tumors and confirmation in animal models Cancer Res 69 2009 8256 8264
8. S.K. Tickoo, M.I. Milowsky, and N. Dhar Hypoxia-inducible factor and mammalian target of rapamycin pathway markers in urothelial carcinoma of the bladder: possible therapeutic implications BJU Int 107 2011 844 849
9. D.E. Hansel, E. Platt, and M. Orloff Mammalian target of rapamycin (mTOR) regulates cellular proliferation and tumor growth in urothelial carcinoma Am J Pathol 176 2010 3062 3072
10. H.L. Fedor, and A.M. De Marzo Practical methods for tissue microarray construction Methods Mol Med 103 2005 89 101
11. L. Schultz, R. Albadine, and J. Hicks Expression status and prognostic significance of mammalian target of rapamycin pathway members in urothelial carcinoma of urinary bladder after cystectomy Cancer 116 2010 5517 5526
12. A.M. Puzio-Kuter, M. Castillo-Martin, and C.W. Kinkade Inactivation of p53 and Pten promotes invasive bladder cancer Genes Dev 23 2009 675 680
13. F.M. Platt, C.D. Hurst, and C.F. Taylor Spectrum of phosphatidylinositol 3-kinase pathway gene alterations in bladder cancer Clin Cancer Res 15 2009 6008 6017
14. D.S. Wang, K. Rieger-Christ, and J.M. Latini Molecular analysis of PTEN and MXI1 in primary bladder carcinoma Int J Cancer 88 2000 620 625
15. M.A. Knowles, F.M. Platt, and R.L. Ross Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer Cancer Metastasis Rev 28 2009 305 316
16. G. Sjodahl, M. Lauss, and S. Gudjonsson A systematic study of gene mutations in urothelial carcinoma; inactivating mutations in TSC2 and PIK3R1 PLoS One 6 2011 e18583
17. C.H. Sun, Y.H. Chang, and C.C. Pan Activation of the PI3K/Akt/mTOR pathway correlates with tumour progression and reduced survival in patients with urothelial carcinoma of the urinary bladder Histopathology 58 2011 1054 1063
18. L.D. Harris, J. De La Cerda, and T. Tuziak Analysis of the expression of biomarkers in urinary bladder cancer using a tissue microarray Mol Carcinog 47 2008 678 685
19. H. Tsuruta, H. Kishimoto, and T. Sasaki Hyperplasia and carcinomas in Pten-deficient mice and reduced PTEN protein in human bladder cancer patients Cancer Res 66 2006 8389 8396
20. I.T. Koksal, D. Yasar, and E. Dirice Differential PTEN protein expression profiles in superficial versus invasive bladder cancers Urol Int 75 2005 102 106
21. R. Rotterud, S.D. Fossa, and J.M. Nesland Protein networking in bladder cancer: immunoreactivity for FGFR3, EGFR, ERBB2, KAI1, PTEN, and RAS in normal and malignant urothelium Histol Histopathol 22 2007 349 363
22. G.J. Netto Molecular biomarkers in urothelial carcinoma of the bladder: are we there yet? Nat Rev Urol 9 2011 41 51
23. I. Ahmad, J.P. Morton, and L.B. Singh beta-Catenin activation synergizes with PTEN loss to cause bladder cancer formation Oncogene 30 2011 178 189
24. L. Cheng, R.M. Neumann, and A.L. Weaver Grading and staging of bladder carcinoma in transurethral resection specimens. Correlation with 105 matched cystectomy specimens Am J Clin Pathol 113 2000 275 279